scholarly journals The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status

Haematologica ◽  
2017 ◽  
Vol 102 (11) ◽  
pp. e447-e451 ◽  
Author(s):  
Anna Vidal-Crespo ◽  
Vanina Rodriguez ◽  
Alba Matas-Cespedes ◽  
Eriong Lee ◽  
Alfredo Rivas-Delgado ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Mantle Cell Lymphoma ◽  
Kinase Inhibitor ◽  
Cell Lymphoma ◽  
Nuclear Factor Κb ◽  
Nuclear Factor ◽  
Mutational Status ◽  
Mantle Cell ◽  
Bruton Tyrosine Kinase

scholarly journals Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Blood ◽  
2013 ◽  
Vol 122 (14) ◽  
pp. 2412-2424 ◽  
Author(s):  
Betty Y. Chang ◽  
Michelle Francesco ◽  
Martin F. M. De Rooij ◽  
Padmaja Magadala ◽  
Susanne M. Steggerda ◽  
...  
Keyword(s):  
Tyrosine Kinase Inhibitor ◽  
Mantle Cell Lymphoma ◽  
Peripheral Blood ◽  
Kinase Inhibitor ◽  
Cell Lymphoma ◽  
Key Points ◽  
Mantle Cell ◽  
Bruton Tyrosine Kinase ◽  
Btk Inhibitor ◽  
And Migration

Key Points MCL cells are mobilized into the peripheral blood of patients treated with the BTK inhibitor ibrutinib. Ibrutinib dose-dependently inhibits BCR- and chemokine-mediated adhesion and migration of MCL cells.

Sign in / Sign up

Export Citation Format

Share Document